-+ 0.00%
-+ 0.00%
-+ 0.00%

Savara says Europe, Australia grant MOLBREEVI liquid formulation patents through 2041

PUBT·07/30/2026 12:11:52
Listen to the news
Savara says Europe, Australia grant MOLBREEVI liquid formulation patents through 2041
  • Savara secured granted patents in Europe and Australia covering the liquid formulation of MOLBREEVI, extending protection through March 2041.
  • The Europe grant is European patent No. 4121000; the Australia grant is patent No. 62/990,810.
  • The announcement strengthens intellectual property coverage for MOLBREEVI outside the US as Savara advances related US filings.
  • Savara cited a separate joint European patent with PARI for a MOLBREEVI drug-device combination, running through March 2043.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607300805BIZWIRE_USPR_____20260730_BW546415) on July 30, 2026, and is solely responsible for the information contained therein.